DNLI
Price
$14.64
Change
+$0.47 (+3.32%)
Updated
Jul 16, 03:27 PM (EDT)
Capitalization
2.06B
15 days until earnings call
TARS
Price
$40.58
Change
-$0.95 (-2.29%)
Updated
Jul 15 closing price
Capitalization
1.74B
22 days until earnings call
Interact to see
Advertisement

DNLI vs TARS

Header iconDNLI vs TARS Comparison
Open Charts DNLI vs TARSBanner chart's image
Denali Therapeutics
Price$14.64
Change+$0.47 (+3.32%)
Volume$900
Capitalization2.06B
Tarsus Pharmaceuticals
Price$40.58
Change-$0.95 (-2.29%)
Volume$538.93K
Capitalization1.74B
DNLI vs TARS Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TARS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. TARS commentary
Jul 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and TARS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 16, 2025
Stock price -- (DNLI: $14.17 vs. TARS: $40.58)
Brand notoriety: DNLI and TARS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 99% vs. TARS: 88%
Market capitalization -- DNLI: $2.06B vs. TARS: $1.74B
DNLI [@Biotechnology] is valued at $2.06B. TARS’s [@Biotechnology] market capitalization is $1.74B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileTARS’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • TARS’s FA Score: 0 green, 5 red.
According to our system of comparison, both DNLI and TARS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while TARS’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • TARS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, TARS is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -0.56% price change this week, while TARS (@Biotechnology) price change was +2.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.65%. For the same industry, the average monthly price growth was +10.09%, and the average quarterly price growth was +39.04%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

TARS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.06B) has a higher market cap than TARS($1.75B). TARS YTD gains are higher at: -26.711 vs. DNLI (-30.471). TARS has higher annual earnings (EBITDA): -94.96M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. TARS (408M). DNLI has less debt than TARS: DNLI (48.6M) vs TARS (72.4M). TARS has higher revenues than DNLI: TARS (234M) vs DNLI (0).
DNLITARSDNLI / TARS
Capitalization2.06B1.75B118%
EBITDA-505.16M-94.96M532%
Gain YTD-30.471-26.711114%
P/E RatioN/AN/A-
Revenue0234M-
Total Cash818M408M200%
Total Debt48.6M72.4M67%
FUNDAMENTALS RATINGS
DNLI: Fundamental Ratings
DNLI
OUTLOOK RATING
1..100
4
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNLITARS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 14 days ago
83%
Declines
ODDS (%)
Bearish Trend 10 days ago
80%
Bearish Trend 6 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bearish Trend 7 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TARS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCLIX59.31N/A
N/A
Fidelity Advisor Industrials I
HBLSX14.80N/A
N/A
Hartford Balanced Income R4
VSCRX57.26N/A
N/A
Virtus KAR Small-Cap Core R6
ICEUX44.01-0.21
-0.47%
NYLI Epoch International Choice Class I
JDDVX12.57-0.12
-0.95%
Janus Henderson U.S. Dividend Income D

TARS and

Correlation & Price change

A.I.dvisor indicates that over the last year, TARS has been loosely correlated with ADMA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if TARS jumps, then ADMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TARS
1D Price
Change %
TARS100%
-2.29%
ADMA - TARS
44%
Loosely correlated
-3.75%
CRNX - TARS
38%
Loosely correlated
-3.60%
OCUL - TARS
37%
Loosely correlated
-1.60%
RYTM - TARS
37%
Loosely correlated
+0.24%
DNLI - TARS
37%
Loosely correlated
-3.54%
More